Mirion Q3 2026 slides: nuclear orders surge 105%, guidance raised

Mirion Technologies reported Q3 2026 revenue of $277.8 million, up 24.5% year over year, and raised 2026 revenue-growth guidance to 24–25% and organic-growth guidance to 7–8%; orders rose 62% organically, including a 105% increase in Nuclear Power demand. Adjusted EBITDA was $64.8 million, up 23.7%, while adjusted EPS was $0.12, in line with expectations. The company also launched a new $250 million share-repurchase program and raised adjusted free-cash-flow guidance to $170–185 million; shares rose 4.4% to $16.13 after the release.

Analysis

MIR: backlog quality, not the nuclear headline, is the trade. The key underwriting question is whether the order surge converts into organic revenue and cash without a lasting margin penalty. Near-term revenue is unusually well covered, so upside likely depends less on another guidance raise and more on 2027 conversion, organic growth, and evidence that digital I&C work scales profitably. Orders can be lumpy; EDF awards awaiting EU funding are a timing risk, not bankable backlog yet. Verify cancellations, conversion schedules, and the organic/acquisition mix before extrapolating headline order growth.

The second-order benefit accrues to nuclear instrumentation and control suppliers if fleet-life extensions and uprates move from announcements to funded projects. CEG and VST’s capacity plans may support that demand, but their economics are not equivalent to MIR’s supplier exposure; the power buyers’ agreements alone do not establish MIR revenue. Conversely, utilities delaying capex or project funding could push supplier revenue out while fixed integration and digital investment costs weigh on margins.

At 3.1x leverage, repurchases compete with deleveraging and acquisition capacity; strong free cash flow helps, but the stated year-end leverage path assumes no further buybacks or M&A. The 4.4% reaction is not enough to judge valuation without a multiple and forward estimates. Over 1–3 months, watch Q4 organic growth and cash conversion; over 6–18 months, test whether backlog converts and margins recover. Falsifiers: organic growth misses guidance, backlog conversion slips, or leverage fails to decline as planned.

Key Decisions for Investors

• MIR: avoid chasing the post-results move; consider a staged long on weakness only if price holds up and Q4 organic growth tracks the mid-to-high-teens outlook. Upside requires conversion into 2027; downside is a delay in awards or renewed margin pressure.
• Track reported organic revenue, orders excluding acquisitions, and cash conversion separately. Treat order growth as an alert—not proof of durable earnings—until conversion is visible; specifically monitor EDF funding decisions and the share of backlog scheduled beyond 2027.
• Do not underwrite the new buyback as an automatic catalyst. Reassess if net leverage does not trend toward management’s year-end target, or if additional repurchases/M&A displace debt reduction.
• No direct AMZN, GOOG, CEG, or VST trade from this report alone: their nuclear-power arrangements support a demand backdrop but do not quantify company-specific earnings exposure.